Foreign investment in pharma; walking a thin line - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Foreign investment in pharma; walking a thin line

Oct 9, 2013

Here is today's recommended reading list from Equitymaster...

Are strict regulations stifling investment in retail?
Walmart put its retail venture in India on the backburner and ended its joint venture with Bharti Enterprises. The world's largest retailer cited the mandatory requirement of 30% of the product sourcing from local businesses as an impediment as it does not provide a level playing field. The opening of FDI in multi-brand retail last year has failed to attract large foreign chains due to the changed government regulations. Read on to know more... (The New York Times Company)

Foreign investment in pharma; walking a thin line
The 100% FDI in the pharma sector has seen a clutch of big-ticket acquisition of domestic companies by foreign multinationals since 2008. However, the health ministry is concerned that foreign companies have not invested in creating new capacities, research & development and in turn new employment in the country. Moreover, with the market share of multinationals going up in the Indian pharmaceutical markets, domestic capability will dwindle and keeping prices of essential drugs under control will become difficult. The DIPP has suggested new rules for FDI to check this. But will this dent the inflow of foreign capital in the long run. Read on to know more. (The Economist Intelligence Unit Limited)

The conundrum of equity returns
What factors influence the return on equity? The author of the article believes that return on equity does not depend on the GDP growth of the economy. The only reason, equity as an asset class tends to offer high returns is the significantly high risk element carried by it. Read on to know more. (GMO)

Will US stimulus measures be pulled back soon?
Speculations about the pullback of stimulus measures have kept global markets on the edge. However the recent development arising out of the US shutdown has lent credence to the winding up program being deferred. The US shutdown has economic costs in terms of lost growth. Therefore longer the shutdown, higher is magnitude of the losses incurred. Therefore to soften the blow, the Fed may continue its stimulus program. Apart from that factors such as absence of data during the shutdown and leadership change may lead to the stimulus program being extended until 2014, feels the author. Read on to know more... (Cable News Network)

Is India's macro economic situation improving?
Aided by lower imports of gold and oil coupled with jump in exports, India's trade deficit in September reduced substantially. This has increased hopes for an improvement in the country's otherwise gloomy economic outlook. Read on to find out more about this strong rebound. (Dow Jones & Company)

Madhu Gupta

Madhu Gupta (Research Analyst), ValuePro has a post graduate degree in both physics and finance. Having worked with India's leading economic research agency, she has a natural flair for numbers and analytics. She brings with her a near-decade long rich experience in the field of finance. A firm believer of the principles of value investing, she looks for robust businesses with durable competitive advantages.

Disclaimer:
This article is for information purposes only. The link in this article will let the User leave www.equitymaster.com and proceed to the linked article. The User's use of each such site is subject to Terms of Use on www.equitymaster.com and other terms of use, if any, contained within each such site. Any data and charts if used, in the article have not been authenticated by Equitymaster and Equitymaster do not claim it to be accurate nor accept any responsibility for the same. The views, if any in the linked article are not of Equitymaster. Equitymaster will not be responsible for any loss or liability incurred to any person as a consequence of his or any other person on his behalf taking any investment decisions based on this article. Please read the detailed Terms of Use of the web site.


Equitymaster requests your view! Post a comment on "Foreign investment in pharma; walking a thin line". Click here!

  

More Views on News

ADVANCED ENZYME TECHNOLOGIES Share Price Up by 10%; BSE HEALTHCARE Index Up 0.4% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

ADVANCED ENZYME TECHNOLOGIES share price is trading up by 10% and its current market price is Rs 302. The BSE HEALTHCARE is up by 0.4%. The top gainers in the BSE HEALTHCARE Index is ADVANCED ENZYME TECHNOLOGIES (up 10.0%). The top losers are CADILA HEALTHCARE (down 0.1%) and APOLLO HOSPITALS (down 0.2%).

GRANULES INDIA Share Price Up by 6%; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Sep 25, 2020 | Updated on Sep 25, 2020

GRANULES INDIA share price is trading up by 6% and its current market price is Rs 395. The BSE HEALTHCARE is up by 1.3%. The top gainers in the BSE HEALTHCARE Index is GRANULES INDIA (up 5.8%). The top losers are ABBOTT INDIA (down 0.2%) and ALKEM LABORATORIES (down 0.8%).

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Sep 25, 2020 11:59 AM

MARKET STATS